Table 2. Survival outcomes for studies included in quantitative analysis.
| Author | Year | Number of patients (n) (HIPEC) | Number of patients (n) (no HIPEC) | 1 y OS (n) HIPEC | 1 y OS (n) no HIPEC | 2 y OS (n) HIPEC | 2 y OS (n) no HIPEC | 3 y OS (n) HIPEC | 3 y OS (n) no HIPEC | 5 y OS (n) HIPEC | 5 y OS (n) NO HIPEC | Median OS HIPEC (months) | Median OS non-HIPEC (months) | Chemoterapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Safra T | 2014 | 27 | 84 | 27 | 81 | 27 | 79 | 25 | 67 | 21 | 38 | 61,6 | 47.7 | Cisplatin + doxorubicin; carboplatin; cisplatin + mitomycin-C |
| Spiliotis J | 2015 | 60 | 60 | 57 | 46 | 54 | 42 | 45 | 11 | 42 | 0 | 26.6 | 15.2 | Cisplatin + paclitaxel |
| Fagotti A | 2012 | 30 | 37 | 30 | 35 | 29 | 28 | 26 | 24 | 20 | 16 | 84 | 54 | Oxaliplatin |
| Baiocchi G | 2016 | 29 | 50 | 25 | 43 | 24 | 37 | 23 | 35 | 14 | 25 | 58.3 | 59.3 | Cisplatin + mitomycin-C |
| Amira G | 2019 | 15 | 20 | 15 | 20 | 14 | 17 | 11 | 13 | 3 | 7 | 36 | 38 | N.A. |
| Muñoz-Casares FC | 2009 | 14 | 12 | 13 | 12 | 12 | 12 | 10 | 3 | 8 | 2 | 132 | 60 | Paclitaxel |
| Le Brun JF | 2014 | 23 | 19 | 23 | 17 | 20 | 12 | 23 | 9 | 17 | 0 | N.A. | N.A. | Carboplatin + paxitaxel; carboplatin + doxorubicin |
OS, overall survival; 1 y OS, 1-year overall survival; 2 y OS, 2-year overall survival; 3 y OS, 3-year overall survival; 5 y OS, 5-year overall survival; chemotherapy, chemotherapy administered with HIPEC; N.A., not available.